miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
May 31, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 31, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
May 16, 2018 17:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 09, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
MRG-110 advanced into clinical development with the initiation of two Phase 1 clinical trials in collaboration with ServierPreclinical data released in two separate ophthalmology programs targeting...
miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
May 08, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
Treatment resulted in durable improved quality of lifeCobomarsen continued to be generally well tolerated at all dose levels evaluatedAdvancing into a Phase 2 clinical trial in second half of 2018 ...
miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases
May 02, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
Dosing with microRNA mimics of the microRNA-183/96/182 cluster led to functional improvement of photoreceptors and vision in retinal degeneration modelMRG-201 dosing inhibited the expression of...
miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018
May 02, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110
May 01, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., May 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics to Participate in Upcoming Investor Conferences
April 30, 2018 16:05 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., April 30, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
April 27, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
MRG-110 appeared to increase vascularization and reparative tissue formation in treated wounds; miRagen believes results support evaluation in human clinical trialsMRG-110 treatment appeared to lead...
miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings
April 19, 2018 07:00 ET
|
Miragen Therapeutics, Inc.
BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...